Pfizer Inc. (NYSE: PFE) announced publication of results in The Lancet Neurologyfrom the Phase 3 pivotal clinical trial of zavegepant, an investigational calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine. The study met its co-primary endpoints, showing that a single 10 mg dose of zavegepant was more effective than placebo for both pain freedom and freedom from the most bothersome symptom (MBS) at two hours post-dose.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a donation to Türkiye and Syria with a total value of 1.5 million Swiss Francs. This includes medicines, other products and financial support. Among others, we are committed to donating 120,000 packages of Rocephin, a critical antibiotic used to treat the symptoms of many kinds of bacterial infections and listed on the World Health Organization's list of essential medicines.

The European Commission granted approval for a label extension for Kerendia™ (finerenone) in the European Union (EU) to include results on cardiovascular (CV) outcomes from the Phase III FIGARO-DKD study. The study demonstrated that Kerendia reduced the risk of CV events in a broad population of patients with stages 1-4 CKD and T2D.

GSK plc (LSE/NYSE: GSK) announced results from a retrospective study on clinical trial diversity, investigating the historical representation of US-based participants in GSK clinical trials. The study looked at clinical trial demographic data from 495 GSK and ViiV clinical trials involving US-based participants from the period 2002 to 2019.

The Bayer Foundation has presented the Otto Bayer Award, complete with its prize money of 75,000 euros, to Professor Frank Glorius. The research scientist at the University of Münster received the award in recognition of the development of an extensive array of groundbreaking catalytic reactions for organic synthesis, facilitating the sustainable synthesis of organic molecules with high levels of selectivity and purity that offer outstanding value for medical and agricultural applications.

Pfizer Inc. (NYSE: PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance. Full-year 2022 revenues of $100.3 billion, an all-time high for Pfizer, reflecting 30% operational growth (excluding contributions from Paxlovid and Comirnaty, revenues grew 2% Operationally).

Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the United States. AMJEVITA was the first biosimilar to Humira approved by the U.S. Food and Drug Administration (FDA), in 2016.(1,2)